ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > PMN has quality science

<< Previous

Bullboard Posts

Next >>

Comment by Actuarialon Dec 09, 2020 10:27am

119 Views

Post# 32066782

RE:PMN has quality science

No one question the science, we just question if the management team ever be able to bring PMN through clinical ...... with no cash, no plan ......

Gbathat wrote: For those who question the level of science from PMN, and who are not convinced by the featured presentations by Dr. Cashman at the leading symposia in this field, I'd like to point out the that PMN310 paper was published in one of the most rigorously peer reviewed journals in the world.

https://www.nature.com/srep/about

Scientific Reports is the 7th most-cited journal in the world, with more than 350,000 citations in 2019*, and receives widespread attention in policy documents and the media.

Here is a link to the article
https://pubmed.ncbi.nlm.nih.gov/31285517/